A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.
Study sponsor: Kodiak Sciences Inc · KOD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-11-17Actual
Enrollment · participants559Actual
Source updated2024-07-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.